Evaxion Biotech (EVAX) Announces Clinical Collaboration with Merck (MRK) to Evaluate Lead Product Candidate with KEYTRUDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Evaxion Biotech (EVAX) Announces Clinical Collaboration with Merck (MRK) to Evaluate Lead Product Candidate with KEYTRUDA

Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma

October 25, 2021 5:30 AM EDT

COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), to evaluate the combination of Evaxions cancer immunotherapy EVX-01 with MSDs anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new Phase 2b study.

The planned... More